^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastroesophageal Junction Adenocarcinoma

    Related cancers:
    13h
    Preclinical characterization and phase 1 results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors. (PubMed, Ann Oncol)
    TQB2102 demonstrates a manageable safety profile and preliminary antitumor activity in advanced solid tumors. A phase 3 trial in patients with HER2-low MBC has been initiated.
    P1 data • Preclinical • Journal • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD4 (CD4 Molecule)
    |
    HER-2 positive
    |
    TQB2102
    16h
    Biomarker-Driven Management of Nonmetastatic GEJ Adenocarcinoma. (PubMed, Ann Surg Oncol)
    These guidelines provide evidence-based recommendations to support precision oncology in GEJ cancer care.
    Review • Journal • MSi-H Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    19h
    Trastuzumab in Addition to Chemotherapy in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Gastroesophageal Cancer-A Real-World Experience. (PubMed, Clin Oncol (R Coll Radiol))
    Our data support the results from the ToGA trial in a real-world cohort and underline the importance of HER2 testing and administration of trastuzumab in clinical routine. Although not included in the initial ToGA trial, oesophageal adenocarcinoma patients express HER2 to a significant extent, and further analyses are needed to investigate the benefit of trastuzumab and other anti-HER2 treatment options in this subgroup.
    Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression • EGFR positive
    |
    Herceptin (trastuzumab)
    3d
    A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=37 --> 20
    Enrollment closed • Enrollment change
    |
    paclitaxel • Cyramza (ramucirumab) • balstilimab (AGEN2034) • botensilimab (AGEN1181) • AgenT-797
    4d
    Single-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial (clinicaltrials.gov)
    P=N/A, N=90, Recruiting, First Affiliated Hospital of Wenzhou Medical University
    New trial
    5d
    A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001) (clinicaltrials.gov)
    P3, N=464, Active, not recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    paclitaxel • irinotecan • Lonsurf (trifluridine/tipiracil) • arcotatug tavatecan (TAK-921)
    5d
    JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=600, Not yet recruiting, NingBo Junyan Hongshi Biosciences Co., Ltd
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 negative • CLDN18.2 positive
    |
    Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • capecitabine • oxaliplatin
    5d
    Impact of Pharmacogenetic Markers on the Efficacy of Neoadjuvant FLOT Chemotherapy in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma. (PubMed, Int J Mol Sci)
    No significant PFS differences by ERCC1 genotype were observed (p = 0.525). ERCC1 (rs11615) may serve as a potential pharmacogenetic marker of response to FLOT, supporting further research in personalized treatment strategies.
    Journal
    |
    ERCC1 (Excision repair cross-complementation group 1) • GSTP1 (Glutathione S-transferase pi 1) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5)
    5d
    Bispecific Antibodies and Antibody-Drug Conjugates in Advanced Gastric Adenocarcinoma. (PubMed, Cancers (Basel))
    Along with these developments in drug therapy, more therapies directed at CLDN18.2, HER2, MSI, EGFR, HER3 and trophoblast cell-surface antigen 2 (TROP2) are underway. Here we review future areas in advanced GAC, including zanidatamab's potential role in HER2-positive advanced GAC and deciphering the abundance of anti-CLDN18.2, extending beyond investigative therapies.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • CLDN18 (Claudin 18)
    |
    HER-2 positive
    |
    Ziihera (zanidatamab-hrii)
    6d
    Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients (clinicaltrials.gov)
    P2, N=110, Completed, Hutchison Medipharma Limited | Active, not recruiting --> Completed | N=75 --> 110 | Trial completion date: Dec 2026 --> Apr 2026 | Trial primary completion date: Dec 2026 --> Apr 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification
    |
    Orpathys (savolitinib)
    6d
    Neoadjuvant SHR-A1811 and SHR-A1701 for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Herceptin (trastuzumab) • trastuzumab rezetecan (SHR-A1811) • retlirafusp alfa (SHR-1701)
    7d
    Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (clinicaltrials.gov)
    P1/2, N=1410, Active, not recruiting, Klus Pharma Inc. | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HER-2 negative • HER-2 expression • HER-2 negative + ER positive
    |
    Jiataile (sacituzumab tirumotecan)